Lorlatinib combined with ramucirumab for ALK lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two targeted drugs, lorlatinib and ramucirumab, for people with ALK-positive lung cancer. It may be a new option if you have not had treatment yet or if a previous ALK medicine stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced lung cancer (non-small cell) that has spread or come back, with a specific ALK gene change (ALK fusion).
- You have not taken lorlatinib or ramucirumab before.
- Your cancer is measurable (can be seen on scans) and you have not had radiation to the spot being measured.
- You are generally healthy enough for daily activities (Karnofsky score of 70% or higher).
- Your blood counts, kidney, and liver function are within certain limits, and you have no major bleeding or clotting problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with advanced lung cancer whose tumors have an ALK gene change and who have already taken a medicine called lorlatinib. It tests a new drug, iruplinalkib, to see how well it works for those who stopped responding to or couldn't tolerate lorlatinib.
This trial tests a combination of two drugs for people with a specific type of advanced lung cancer that has a change in the ALK gene. The goal is to see if this combination works better than current treatments and to use a blood test to guide therapy.
This study is testing a targeted therapy called lorlatinib in people with advanced ALK-positive lung cancer. It aims to see how well this oral medication works in a real-world setting.
This trial tests combining chemotherapy with lorlatinib for people with ALK-positive lung cancer that has spread outside the brain while on lorlatinib. The goal is to see if adding chemo can help control the cancer when it starts growing again.
This trial tests a targeted pill, lorlatinib, for people with advanced ALK-positive non-small cell lung cancer (NSCLC) who have not received previous treatment for advanced disease. It aims to see how well the drug works in this setting.
This study combines a daily targeted pill (lorlatinib) with a short course of radiation or surgery to treat ALK-positive lung cancer. The goal is to see if this two-step approach delays the cancer from growing.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.